US Stock MarketDetailed Quotes

CRVS Corvus Pharmaceuticals

Watchlist

4.620
+0.240+5.48%

Close Mar 7 16:00 ET

4.620
0.0000.00%

Post 20:01 ET

296.87MMarket Cap-4.67P/E (TTM)

Corvus Pharmaceuticals Stock Forum

71179109

Jan 15 11:24

$Corvus Pharmaceuticals (CRVS.US)$ expecting big pharma will merge this guy

Trytosaveabit

Jan 13 06:33

Update

$Corvus Pharmaceuticals (CRVS.US)$ Reuters· 1 min ago
Corvus Pharmaceuticals Inc - Data Show Favorable Safety and Efficacy Profile

Jaguar8

Jan 13 06:30

NEWS

$Corvus Pharmaceuticals (CRVS.US)$
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Monday, 13th January at 7:30 am
BURLINGAME, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with m...

seer84

Dec 18, 2024 12:19

$Nukkleus (NUKK.US)$
day 2, though im making 1k+ from this NUKE everyday… im just covering loss from pharma… never gonna touch meds again else wld be up 6k+ hahahaha

Share Your Profit/Loss

seer84

Dec 18, 2024 07:17

$Corvus Pharmaceuticals (CRVS.US)$
why everyone are leaving? i thought this is a promising clinical sign???

Trytosaveabit

Dec 18, 2024 06:37

Here it is!

$Corvus Pharmaceuticals (CRVS.US)$ Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile
Data includes complete results from cohort 1 and initial results from cohort 2
Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million
Company to host conference call and webca...

Trytosaveabit

Dec 17, 2024 17:11

Reminder for tomorrow

$Corvus Pharmaceuticals (CRVS.US)$ Corvus Pharmaceuticals to Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Jaguar8

Dec 17, 2024 16:55

🟡Watchlist WEDNESDAY December 18,2024

NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...

Trump announces $500 billion "Stargate" project! Powerful catalyst for AI?

Jaguar8

Dec 17, 2024 15:07

NEWS

$Corvus Pharmaceuticals (CRVS.US)$
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe ...